5PSQ-059 Pharmacist-led observational study on quality of life in relapsing–remitting multiple sclerosis: evidence from the Qosmos study

Background and importancePatient reported outcomes (PRO) are increasingly used to evaluate effectiveness of treatments for multiple sclerosis (MS) and they often include an evaluation of health related quality of life (QoL). In 2017, the Italian Society of Clinical Pharmacy and Therapeutics (SIFaCT) and the National Association of Hospital Pharmacy Students (ReNaSFO) established a joint action to update existing data on QoL and its correlation with use of disease modifying drugs in Italian patients. The results will be helpful as reference for future studies using PRO.Aim and objectivesThe primary endpoint was QoL score in MS patients. Secondary objectives included QoL correlation with pharmacological therapy and clinical characteristics of patients.Material and methodsWe designed a multicentre, observational, cross sectional study. Every patient had to complete a questionnaire on QoL (MS-QoL54) and the pharmacist collected the following data: sex, age, MS type, expanded disability status scale (EDSS) and history of pharmacological treatments. The study was approved by an ethic committee in each centre and patients provided signed informed consent. As MS-QoL54 scores were not normally distributed, we used Spearman’s correlation test, ANOVA on ranks for multiple comparisons and the Mann–Whitney test for simple comparisons.ResultsWe enrolled 341 patients from 16 centres (median age 44.1 years; 68.9% women) with relapsing–remitting MS from May 2018 to June 2019 (median 20 per centre). The composite indexes of physical and mental well being were correlated with each other (R=0.826; p